Circulating Tumor Cell, Colorectal Cancer Stage IV
Conditions
Brief summary
This study enrolling patients with metastatic colorectal cancer. Detecting CTC at different points in the treatment process. Descripting the molecular atlas of CTC in mCRC patients. Building and validating a response prediction system of mCTC patients.
Interventions
DIAGNOSTIC_TESTCirculating tumor cell
Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Age 18-80 years; histologically proven colorectal liver metastasis With liver-dominant disease (extrahepatic metastases limited to lung metastases) ECOG 0-1 A life expectancy of ≥ 3 months Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl Written informed consent for participation in the trial.
Exclusion criteria
* Other previous malignancy within 5 years Have metastases other than liver and lung metastases Receiving any treatment before first blood collection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity | 1 year | The sensitivity of the response prediction model |
| Specificity | 1 year | The specificity of the response prediction model |
Contacts
Primary ContactJianmin Xu
Outcome results
None listed